(Q28307713)

ORCID Public Data File 2021

Peter A. Lewitt

1

object named as

Peter A LeWitt

0 references

author name string

Ali R Rezai

2

0 references

Maureen A Leehey

3

0 references

Steven G Ojemann

4

0 references

Alice W Flaherty

5

0 references

Emad N Eskandar

6

0 references

Sandra K Kostyk

7

0 references

Karen Thomas

8

0 references

Atom Sarkar

9

0 references

Mustafa S Siddiqui

10

0 references

Jason M Schwalb

12

0 references

Kathleen L Poston

13

0 references

Jaimie M Henderson

14

0 references

Roger M Kurlan

15

0 references

Irene H Richard

16

0 references

Lori Van Meter

17

0 references

Christine V Sapan

18

0 references

Matthew J During

19

0 references

Michael G Kaplitt

20

0 references

Andrew Feigin

Levodopa for the treatment of Parkinson's disease

21

0 references

language of work or name

English

0 references

publication date

April 2011

0 references

published in

Lancet Neurology

0 references

volume

10

0 references

issue

4

0 references

page(s)

309-19

0 references

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Motor fluctuations and dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

What's in the pipeline for the treatment of Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Cellular principles underlying normal and pathological activity in the subthalamic nucleus.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

The subthalamic nucleus in the context of movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

A randomized trial of deep-brain stimulation for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Subthalamic GAD gene therapy in a Parkinson's disease rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

A clinicopathologic study of 100 cases of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Studies of interference in serial verbal reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

The clinically important difference on the unified Parkinson's disease rating scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970039-4

7 January 2021

10.1016/S1474-4422(11)70039-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

920513

920513

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference